Search Within

Takeshi Shimamura

Refine Results
  1. "Cancer research"
Formats
  1. Journal Article (6)
Groups
  1. Cardinal Bernardin Cancer Center (6)
  2. Oncology Research Institute (6)
People
  1. Michael Nishimura (1)
  2. Simon Kaja (1)
  3. Tarun Patel (1)
  4. Wei Qiu (1)
  5. Yuk-Ming Liu (1)
Years
  1. 2020 (1)
  2. 2016 (2)
  3. 2015 (1)
  4. 2013 (1)
  5. 2012 (1)
Journals
  1. Cancer research (6)
Publishers
  1. AACR (4)
  2. American Association for Cancer Research (2)

Results (6)

  • Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC.
    Journal Article

    Pulido, I; Ollosi, S; Aparisi, S; Becker, JH; Aliena-Valero, A; Benet, M; Rodríguez, ML; López, A; Tamayo-Torres, E; Chuliá-Peris, L; more...
    Cancer research (2020)

    Find It @ Loyola | Save
  • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
    Journal Article

    Koyama, S.; Akbay, E. A.; Li, Y. Y.; Aref, A. R.; Skoulidis, F.; Herter-Sprie, G. S.; Buczkowski, K. A.; Liu, Y; Awad, M. M.; Denning, W. L.; more...
    Cancer research (2016)

    Find It @ Loyola | Save
  • Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Response
    Journal Article

    Shimamura, T
    Cancer research (2016)

    Find It @ Loyola | Save
  • Intratumoral heterogeneity in EGFR mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition
    Journal Article

    Soucheray, M; Capelletti, M.; Pulido, I; Kuang, Y.; Paweletz, C. P.; Becker, J. H.; Kikuchi, E.; Xu, C.; Patel, T. B.; Al-Shahrour, F; more...
    Cancer research (2015)

    Find It @ Loyola | Save
  • Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
    Journal Article

    Cortot, A. B.; Repellin, C. E.; Shimamura, T; Capelletti, M.; Zejnullahu, K.; Ercan, D.; Christensen, J. G.; Wong, K. K.; Gray, N. S.; Janne, P. A.
    Cancer research (2013)

    Find It @ Loyola | Save
  • Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
    Journal Article

    Xu, L; Kikuchi, E.; Xu, C.; Ebi, H.; Ercan, D.; Cheng, K. A.; Padera, R.; Engelman, J. A.; Janne, P. A.; Shapiro, G. I.; more...
    Cancer research (2012)

    Find It @ Loyola | Save